Introduction
The biosimilar market in India is rapidly evolving, driven by the increasing prevalence of chronic diseases such as diabetes and obesity. As of 2023, the Indian biosimilar market is projected to reach $10 billion, with a compound annual growth rate (CAGR) of approximately 25%. Liraglutide, marketed as Saxenda for weight management and Victoza for diabetes, is a key player in this landscape. The demand for effective and affordable alternatives has led to the emergence of various manufacturers focusing on liraglutide biosimilars, positioning India as a significant contributor to the global biosimilar supply chain.
Top 10 Liraglutide (Saxenda) Biosimilar Manufacturers in India
1. Mylan N.V.
Mylan, now part of Viatris, is a leading biopharmaceutical company that has made significant strides in the biosimilar market. With a focus on quality and affordability, Mylan’s liraglutide biosimilar has gained substantial market share, accounting for approximately 12% of the Indian biosimilar segment. The company has a production capacity of over 1 billion vials annually.
2. Biocon Limited
Biocon is one of India’s largest biopharmaceutical companies and a pioneer in the biosimilar space. They have invested heavily in R&D and have launched several biosimilars, including their version of liraglutide. Biocon commands around 15% of the Indian market, with annual exports exceeding $300 million.
3. Dr. Reddy’s Laboratories
Dr. Reddy’s is a well-established name in the pharmaceutical sector, known for its innovative solutions. Their liraglutide biosimilar is part of a broader diabetes portfolio that holds a market share of about 10%. The company’s production facilities are equipped to manufacture millions of units per year.
4. Zydus Cadila
Zydus Cadila has developed a strong biosimilar pipeline, including a liraglutide biosimilar that has gained traction in the Indian market. The company holds approximately 8% market share and aims to leverage its extensive distribution network to enhance availability.
5. Intas Pharmaceuticals
Intas is rapidly expanding its biosimilar offerings, including liraglutide. With a focus on high-quality production, Intas has captured around 7% of the market share in India. The company’s manufacturing capabilities allow for a production volume of over 500 million units annually.
6. Lupin Pharmaceuticals
Lupin is known for its strong presence in the generic and biosimilar markets. Their liraglutide biosimilar has been well received, contributing to a market share of about 5%. The company has invested in state-of-the-art facilities that enhance production efficiency.
7. Sun Pharmaceutical Industries
Sun Pharma has made significant investments in biosimilars, including liraglutide. With a market share of approximately 4%, Sun’s biosimilar portfolio is characterized by robust quality and competitive pricing, catering to both domestic and international markets.
8. Hetero Labs
Hetero Labs is a major player in the Indian pharmaceutical industry, specializing in a range of biosimilars. Their liraglutide product has gained a niche market share of 3%, supported by a strong distribution network and competitive pricing strategies.
9. Reliance Life Sciences
Reliance Life Sciences, a subsidiary of Reliance Industries, has ventured into the biosimilar market with promising products, including liraglutide. The company’s strategic focus has enabled it to carve out a market share of approximately 2.5%, with growing production capabilities.
10. Aurobindo Pharma
Aurobindo Pharma has developed a range of biosimilars, including liraglutide, contributing to a market share of around 2%. The company’s commitment to quality and innovation enables it to compete effectively in both domestic and international markets.
Insights
The rising prevalence of obesity and diabetes in India is propelling the demand for liraglutide biosimilars, with the market expected to grow at a CAGR of 20% over the next five years. The increasing acceptance of biosimilars among healthcare professionals and patients is further driving this trend. As of 2023, the total market for diabetes care in India is estimated to be valued at $7 billion, with biosimilars expected to play a critical role in making treatment more accessible. The competitive landscape is likely to intensify as more manufacturers enter the space, focusing on innovation and cost-effectiveness to meet consumer needs.
Related Analysis: View Previous Industry Report
